CALT - Calliditas Therapeutics AB
39.2
0 0%
Share volume: 0
Last Updated: Fri 20 Sep 2024 05:23:14 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.24%
PREVIOUS CLOSE
CHG
CHG%
$39.20
0.00
0.00%
Fundamental analysis
21%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
15%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
0 0%
6 Months
2.41%
1 Year
58.60%
2 Year
120.96%
Key data
Stock price
$39.20
DAY RANGE
N/A - $39.20
52 WEEK RANGE
$18.60 - $43.00
52 WEEK CHANGE
$55.92
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Renée Julie Elisabet Aguiar-Lucander
Region: US
Website: calliditas.se
Employees: 180
IPO year: 2020
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: calliditas.se
Employees: 180
IPO year: 2020
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Calliditas Therapeutics AB (publ) focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy.
Recent news